A non-interventional study looking at safety and efficacy of medicinal cannabis prescribed to patients with symptoms of Irritable Bowel Syndrome (IBS).

Patients referred to Emerald Clinics for the management of IBS symptoms and who are determined to be eligible for medicinal cannabis through the SAS or AP schemes will be offered participation in this observational study. Participants are eligible for the study if they are 18 years or older, meet the Rome IV criteria for IBS of any subtype including IBS with constipation (IBS-C), IBS with diarrhoea (IBS-D), mixed type IBS (IBS-M) or unsubtyped IBS(IBS-U), have had symptoms for more than 6 months, and consent to participate in the study. This is an open-label observational, prospective, longitudinal cohort study of eligible patients treated with cannabinoid medicines at Emerald Clinics to determine if IBS symptoms improve with treatment and if treatment is well tolerated with minimal side effects. Since this is an observational study, product type and dosage is not defined and will be determined by the treating doctor as approved through the TGA SAS and AP scheme. Treatment dosing is in accordance with Emerald clinical experience of dosing titration of cannabinoid medicine until a optimal therapeutic effect is obtained, well-tolerated with minimal side effects. After dosing titration, the doctor will make a recommendation on the optimal dose and the patients will continue on the same product(s) for the 12 week treatment period as tolerated. Dosage and product may continue to be adjusted by the prescribing doctor to optimise effect and minimise adverse events, under the conditions of approval through the TGA SAS and AP. Assessments in this observational study will be conducted weekly using Web Application, with doctor review conducted at baseline, week 2, week 4, week 8 and week 12.